Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration

被引:81
作者
Barron, LG [1 ]
Gagné, L [1 ]
Szoka, FC [1 ]
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
关键词
D O I
10.1089/10430349950017680
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have defined the critical time period for gene delivery in the lung after intravenous administration of cationic lipoplex, We accomplished this through the displacement of intravenously injected cationic lipoplexes from the lungs by the subsequent administration of anionic liposomes, When reporter gene-bearing lipoplexes were injected intravenously and followed by anionic liposomes 5 min later, reporter gene expression was reduced up to 400-fold compared with animals into which lipoplex alone was administered, Administration of anionic liposomes 60-90 min after lipoplex injection yielded no significant reduction in lung transfection, When lipoplexes were disrupted 5 min after administration, the pulmonary distribution of the cationic lipid and DNA components was reduced by 80%, Lipids subsequently accumulated primarily in the liver, while the plasmid DNA constituent distributed into the blood and liver, As the interval between lipoplex and anionic liposome injection increased, the degree of lipoplex displacement from the lung decreased to such a point that, 60 min after lipoplex injection, the anionic liposome injection did not displace significant quantities of the lipoplex, We conclude that cationic lipid-DNA complexes can be disrupted in vivo via the administration of anionic liposomes; moreover, we have employed this phenomenon to demonstrate that transfectionally active DNA is taken up within 60 min of systemic lipoplex administration.
引用
收藏
页码:1683 / 1694
页数:12
相关论文
共 38 条
  • [1] ABRA RM, 1982, RES COMMUN CHEM PATH, V37, P199
  • [2] Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid DNA complexes
    Barron, LG
    Meyer, KB
    Szoka, FC
    [J]. HUMAN GENE THERAPY, 1998, 9 (03) : 315 - 323
  • [3] INHIBITION OF PROTEIN-KINASE-C BY CATIONIC AMPHIPHILES
    BOTTEGA, R
    EPAND, RM
    [J]. BIOCHEMISTRY, 1992, 31 (37) : 9025 - 9030
  • [4] INVIVO TRANSFECTION OF MURINE LUNGS WITH A FUNCTIONING PROKARYOTIC GENE USING A LIPOSOME VEHICLE
    BRIGHAM, KL
    MEYRICK, B
    CHRISTMAN, B
    MAGNUSON, M
    KING, G
    BERRY, LC
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1989, 298 (04) : 278 - 281
  • [5] LIPOSOME-MEDIATED CFTR GENE-TRANSFER TO THE NASAL EPITHELIUM OF PATIENTS WITH CYSTIC-FIBROSIS
    CAPLEN, NJ
    ALTON, EWFW
    MIDDLETON, PG
    DORIN, JR
    STEVENSON, BJ
    GAO, X
    DURHAM, SR
    JEFFERY, PK
    HODSON, ME
    COUTELLE, C
    HUANG, L
    PORTEOUS, DJ
    WILLIAMSON, R
    GEDDES, DM
    [J]. NATURE MEDICINE, 1995, 1 (01) : 39 - 46
  • [6] Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG(5000) formulation to the lungs of normal volunteers
    Chadwick, SL
    Kingston, HD
    Stern, M
    Cook, RM
    OConnor, BJ
    Lukasson, M
    Balfour, RP
    Rosenberg, M
    Cheng, SH
    Smith, AE
    Meeker, DP
    Geedes, DM
    Alton, EWFW
    [J]. GENE THERAPY, 1997, 4 (09) : 937 - 942
  • [7] Nomenclature for synthetic gene delivery systems
    Felgner, PL
    Barenholz, Y
    Behr, JP
    Cheng, SH
    Cullis, P
    Huang, L
    Jessee, JA
    Seymour, L
    Szoka, F
    Thierry, AR
    Wagner, E
    Wu, G
    [J]. HUMAN GENE THERAPY, 1997, 8 (05) : 511 - 512
  • [8] LIPOFECTION - A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE
    FELGNER, PL
    GADEK, TR
    HOLM, M
    ROMAN, R
    CHAN, HW
    WENZ, M
    NORTHROP, JP
    RINGOLD, GM
    DANIELSEN, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7413 - 7417
  • [9] DEXTRAN SULFATE DISPOSITION IN THE RAT
    FOSTER, BC
    GALLICANO, KD
    WHITEHOUSE, LW
    MCGILVERAY, IJ
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (07) : 595 - 606
  • [10] Freimark BD, 1998, J IMMUNOL, V160, P4580